Rational use of the fixed combination of dorzolamide – timolol in the management of raised intraocular pressure and glaucoma
Jason Yeh1, Daniel Kravitz2, Brian Francis11Doheny Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; 2Tulane University, School of Medicine, New Orleans, LA, USAAbstract: Glaucoma is a multifactorial optic neuropathy in which the main therapeutic target...
Guardado en:
Autores principales: | Jason Yeh, Daniel Kravitz, Brian Francis |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/fe8f5b45f7754e48a51a84c257afc82d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
por: Mizoguchi T, et al.
Publicado: (2011) -
A patient preference comparison of Azarga™ (brinzolamide/timolol fixed combination) vs Cosopt® (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension
por: Thomas K Mundorf, et al.
Publicado: (2008) -
Preference for a fixed combination of brinzolamide/timolol versus dorzolamide/ timolol among patients with open-angle glaucoma or ocular hypertension
por: Sanseau A, et al.
Publicado: (2013) -
Intraocular pressure reduction of fixed combination timolol maleate 0.5% and dorzolamide 2% (Cosopt) administered three times a day
por: Moisseiev E, Lazar M, et al.
Publicado: (2012) -
Tolerability and effectiveness of preservative-free dorzolamide–timolol (preservative-free Cosopt®) in patients with open-angle glaucoma or ocular hypertension
por: Cindy Hutnik, et al.
Publicado: (2010)